Panel is out:Center for Drug Evaluation and Research (CDER)
Page 1 of 2
Oncologic Drugs Advisory Committee (ODAC) Roster Chairperson
Philip C. Hoffman, MD
Expertise: Medical Oncology
Term: 4/25/2017 – 6/30/2021
Professor of Medicine The University of Chicago
Section of Hematology/Oncology
Department of Medicine
5841 S. Maryland Avenue, MC 2115
Chicago, Illinois 60637
Designated Federal Officer
She-Chia S. Chen, PharmD
Division of Advisory Committee and Consultant Management Office of Executive Programs
Center for Drug and Evaluation and Research Food and Drug Administration 10903 New Hampshire Avenue
Silver Spring, Maryland 20993 (301) 796-9001 Fax: (301) 847-8533
E-mail: [email protected]
1 Jaffer A. Ajani, MD
Expertise: Medical Oncology
Term: 7/1/2019 – 6/30/2023
Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Professor, Department of Epidemiology, Division
of Office of the Vice President, Cancer Prevention and Population Sciences
University of Texas MD Anderson Cancer Center
1400 Holcombe Blvd., FC10.3022
Houston, Texas 77030
**Jonathan D. Cheng, MD
Expertise: Medical Oncology
Term: 11/1/2019 – 10/31/2023
Vice President and Oncology Therapeutic Area Head, Merck Research Laboratories, Oncology Clinical Research
351 North Sumneytown Pike
North Wales, Pennsylvania 19454
2 Massimo Cristofanilli, MD, FACP
Expertise: Medical Oncology
Term: 9/27/2018 – 6/30/2022
Associate Director of Translational Research and Precision Medicine
Robert H. Lurie Comprehensive Cancer Center
710 North Fairbanks Court, Suite 8-250A
Chicago, Illinois 60611
Jorge A. Garcia, MD, FACP
Expertise: Medical Oncology
Term: 7/1/2019 – 6/30/2023
Chair, Division of Solid Tumor Oncology
George and Edith Richman Distinguished Scientist Chair
Director, GU Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
11100 Euclid Avenue, Lakeside Suite 1200
Cleveland, Ohio 44106
3 Susan Halabi, PhD
Expertise: Biostatistics
Term: 7/1/2017 – 6/30/2021
Professor of Biostatistics and Bioinformatics
Duke University Medical Center
2424 Erwin Road, Suite 11088
Durham, North Carolina 27705
Christian S. Hinrichs, MD
Expertise: Medical Oncology
Term: 9/27/2018 – 6/30/2022
Investigator & Lasker Clinical Research Scholar
Experimental Transplantation and Immunology
Branch
National Cancer Institute
National Institutes of Health
10 Center Drive, Room 4B04
*David E. Mitchell
Expertise: Consumer Representative
Term: 10/22/2019 – 6/30/2024
Founder, Patients for Affordable Drugs
Bethesda, Maryland 20814
Alberto S. Pappo, MD
Expertise: Pediatric Oncology
Term: 6/4/2015 – 6/30/2022
Member and Head, Division of Solid Malignancies
St Jude Children’s Research Hospital
Professor of Pediatrics
University of Tennessee Health Science Center
262 Danny Thomas Place
Memphis, Tennessee 38105
1 Anthony D. Sung, MD
Expertise: Hematology
Term: 7/1/2019 – 6/30/2023
Assistant Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
2400 Pratt Street, Suite 9000, Room 9053
Durham, North Carolina 27705
* Consumer Representative
** Industry Representative (non-voting)
Updated: August 4, 2020
- Forums
- ASX - By Stock
- MSB
- FDA ODAC Meeting Material discussion analysis
FDA ODAC Meeting Material discussion analysis, page-186
-
- There are more pages in this discussion • 306 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B |
Open | High | Low | Value | Volume |
$1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 12214 | $1.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.38 | 37660 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 12214 | 1.375 |
7 | 53796 | 1.370 |
7 | 53347 | 1.365 |
14 | 192096 | 1.360 |
3 | 45165 | 1.355 |
Price($) | Vol. | No. |
---|---|---|
1.380 | 37660 | 5 |
1.385 | 25000 | 1 |
1.390 | 56973 | 4 |
1.395 | 31284 | 2 |
1.400 | 146999 | 10 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online